Gilbert & Cook Inc. Buys Shares of 2,685 Becton, Dickinson and Company (NYSE:BDX)

Gilbert & Cook Inc. purchased a new stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,685 shares of the medical instruments supplier's stock, valued at approximately $647,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Livelsberger Financial Advisory bought a new position in shares of Becton, Dickinson and Company in the 3rd quarter worth about $26,000. Ashton Thomas Securities LLC bought a new stake in Becton, Dickinson and Company during the 3rd quarter valued at approximately $33,000. Tompkins Financial Corp boosted its holdings in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier's stock valued at $36,000 after purchasing an additional 46 shares during the last quarter. Sound Income Strategies LLC raised its stake in Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier's stock valued at $40,000 after purchasing an additional 44 shares in the last quarter. Finally, Kennebec Savings Bank bought a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at approximately $46,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BDX has been the topic of several recent analyst reports. Evercore ISI upped their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. Stifel Nicolaus lifted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a "buy" rating in a research note on Friday, July 26th. Raymond James cut their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an "outperform" rating on the stock in a research report on Friday, August 2nd. StockNews.com upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Thursday, August 8th. Finally, Citigroup upgraded Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $283.00.

Becton, Dickinson and Company Trading Down 0.9 %

Shares of BDX stock traded down $2.02 during trading hours on Friday, reaching $225.15. The company had a trading volume of 1,965,697 shares, compared to its average volume of 1,528,964. The company has a 50 day moving average of $236.30 and a 200 day moving average of $234.99. The firm has a market cap of $65.08 billion, a price-to-earnings ratio of 37.90, a P/E/G ratio of 1.68 and a beta of 0.43. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $249.89. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company's revenue was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.42 earnings per share. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.85%. The ex-dividend date is Monday, December 9th. This is a boost from Becton, Dickinson and Company's previous quarterly dividend of $0.95. Becton, Dickinson and Company's dividend payout ratio is presently 63.97%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.